United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) COO Michael Benkowitz sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $833,350.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
United Therapeutics Trading Down 0.2 %
UTHR opened at $330.26 on Friday. The stock has a market capitalization of $14.69 billion, a PE ratio of 15.62, a P/E/G ratio of 1.17 and a beta of 0.55. The firm’s fifty day moving average price is $313.85 and its 200 day moving average price is $265.03. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $343.98.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company’s revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the company earned $5.24 earnings per share. As a group, research analysts expect that United Therapeutics Co. will post 24.79 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on United Therapeutics
Institutional Trading of United Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of UTHR. ClariVest Asset Management LLC raised its holdings in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC acquired a new stake in shares of United Therapeutics during the second quarter worth $30,000. Rise Advisors LLC acquired a new stake in shares of United Therapeutics during the first quarter worth $32,000. Innealta Capital LLC acquired a new stake in shares of United Therapeutics during the second quarter worth $33,000. Finally, GAMMA Investing LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $43,000. 94.08% of the stock is owned by institutional investors and hedge funds.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
- Five stocks we like better than United Therapeutics
- What is Insider Trading? What You Can Learn from Insider Trading
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Pros And Cons Of Monthly Dividend Stocks
- MarketBeat Week in Review – 8/5 – 8/9
- What is a Bond Market Holiday? How to Invest and Trade
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.